Background: Granulosa cell tumours are rare ovarian malignancies accounting for 2% to 5% of ovarian tumours. They are characterized by late recurrences, with the latest recurrence reported 37 years after first diagnosis.
Case: A 73-year-old woman who had surgery for a granulosa cell tumour in her early 30s and who presented with a recurrence 40 years later.
Conclusion: Patients and their physicians should be made aware that there is a potential for a granulosa cell tumour to recur many years in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1701-2163(16)30464-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ovarian sex cord-stromal cell tumors and the risk of sex hormone-sensitive cancers.
Am J Obstet Gynecol
January 2025
Women's Health, Aabenraa, University Hospital of Southern Denmark; Institute of Regional Health Research, University of South Denmark.
Background: Sex cord-stromal cell tumors (SCST) are rare tumors of the ovary. Some of the SCSTs secrete hormone originating from the sex or stromal cell of the ovaries. Previous studies have indicated an increased risk of breast and endometrial cancers.
View Article and Find Full Text PDFPurpose: To investigate the effects of C-type natriuretic peptide (CNP) on human granulosa cell growth and elucidate its regulatory mechanisms.
Methods: A human non-luteinizing granulosa cell line (HGrC) developed from small antral follicles was used to assess the impact of CNP on cell proliferation and estrogen synthesis. cGMP production via the guanylate cyclase domain of the CNP receptor, natriuretic peptide receptor 2 (NPR2), was confirmed.
Murine Models and Human Cell Line Models to Study Altered Dynamics of Ovarian Follicles in Polycystic Ovary Syndrome.
Adv Biol (Weinh)
January 2025
Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, 67100, Italy.
Polycystic ovary syndrome is one of the most common endocrine disorders in women of reproductive age, characterized by functional and structural alterations of the female reproductive organs. Due to the unknown underlying molecular mechanisms, in vivo murine models and in vitro human cellular models are developed to study the syndrome. These models are used to analyze various aspects of the pathology by replicating the conditions of the syndrome.
View Article and Find Full Text PDFLuteinizing hormone receptor knockout mouse: What has it taught us?
Andrology
January 2025
Department of Digestion, Metabolism and Reproduction, Institute of Reproductive and Developmental Biology, Hammersmith Campus, Imperial College London, London, UK.
Luteinizing hormone (LH), along with its agonist choriongonadotropin (hCG) in humans, is the key hormone responsible for the tropic regulation of the gonadal function. LH and hCG act through their cognate receptor, the luteinizing hormone/choriongonadotropin receptor (LHCGR; more appropriately LHR in rodents lacking CG), located in the testis in Leydig cells and in the ovary in theca, luteal, and luteinizing granulosa cells. Low levels in LHCGR are also expressed in numerous extragonadal sites.
View Article and Find Full Text PDFIntegrated Transcriptome and Proteome Analyses Reveal Differentially Expressed Genes and Proteins in Granulosa Cells from Female Patients with Metabolic Syndrome-associated Infertility.
Curr Med Chem
January 2025
Center of Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Background: Metabolic Syndrome (MS) is a cluster of conditions that significantly increase the risk of infertility in women. Granulosa cells are crucial for ovarian folliculogenesis and fertility. Understanding molecular alterations in these cells can provide insights into MS-associated infertility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!